Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Eur J Appl Physiol. 2012 Oct 30;113(5):1127–1136. doi: 10.1007/s00421-012-2529-z

Table 3.

Enrollment and baseline characteristics of compliant participants

Placebo Acetaminophen p
Randomized (n) 13 13
Withdrawals (n) 2 1
Completed intervention (n) 11 12
Compliant to exercise (n) 7 10
Age (years) 63.3 ± 10.3 64.0 ± 5.8 0.87
BMI (kg/m2) 28.4 ± 4.6 28.9 ± 6.2 0.84
Height (cm) 172.6 ± 9.2 182.8 ± 7.8 0.02
Weight (kg) 85.4 ± 21.5 95.7 ± 16.0 0.27
Fat-free mass (kg) 60.6 ± 12.1 66.2 ± 6.4 0.23
Fat mass (kg) 24.8 ± 10.1 29.5 ± 11.5 0.40
Serum BAP (U/L) 22.7 ± 2.3 25.3 ± 8.8 0.48
Serum CTX (ng/mL) 0.4 ± 0.2 0.4 ± 0.2 0.99

Compliance was defined as attending at least 80 % of exercise sessions

BAP bone-specific alkaline phosphatase, CTX C-terminal cross links of type-I collagen